TG Therapeutics

Nasdaq: TGTX · SEC EDGAR filings

Results on file1
Average 24h move−0.97%across 1 result with a complete 24h price
1 resultTG Therapeutics
Met endpoint

ublituximab

Phase 3 Relapsing Forms of Multiple Sclerosis

TG Therapeutics TGTX

24h stock move −0.97%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.